Raghu Saripalli

Co-founder, President and CEO


Raghu Saripalli, co-founder, Chief Executive Officer, and President of Aspera Biomedicines, has 20+ years of experience in biotech finance and operations. He was a co-founder of Impact Biomedicines, that was acquired by Celgene in 2018. Impact’s lead candidate for treatment of myelofibrosis, Inrebic® was approved for sale in the US, Canada and Europe. Throughout his career, he has successfully raised more than $500 million, demonstrating his expertise in securing funding and managing financial strategies within the biotech sector. Mr. Saripalli has an MBA from the Wharton School of the University of Pennsylvania and dual MS degrees in Mechanical Engineering and Computer Science from Virginia Tech University.


Per Aspera Ad AstraThrough Hardship to the Stars

From investors to collaborators, connectwith Aspera to accelerate breakthroughs!

Contact Us